An 18 Month Open Label Study Of The Tolerability And Efficacy Of An Antisense Oligonucleotide In Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy (Senile Systemic Amyloidosis)

Trial Profile

An 18 Month Open Label Study Of The Tolerability And Efficacy Of An Antisense Oligonucleotide In Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy (Senile Systemic Amyloidosis)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Inotersen (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 09 Aug 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 17 Dec 2015 According to an Isis Pharmaceuticals media release, data from this study can be used to support regulatory filings for ISIS-TTRrx in all patients with TTR amyloidosis.
    • 15 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top